Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40+
SponsorMonash University
About this trial
This study is a prospective observational study evaluating the natural history of coronary plaque burden in participants with melanoma treated with ICI. The study will be conducted at various sites across Australia.
Eligibility criteria
Qualifiers
Capable of providing informed consent and willing to adhere to all protocol requirements
patients aged > or equal to 40 years
Histologically confirmed melanoma of any stage planned for, commenced, or completed treatment with ICI
having acceptable imaging quality deemed by the core laboratory
Disqualifiers
Known clinically manifest cardiovascular disease
Female participants must not be pregnant, breastfeeding or plan to become pregnant during the study.
Estimated glomerular filtration rate of <45 mL/min calculated using the Chronic Kidney Disease Epidemiology Collaboration equation
Severe liver disease or cirrhosis
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Monash University
Lead sponsor
National Health and Medical Research Council, Australia
Collaborator
Source ClinicalTrials.gov